chemotheraphy

PHILADELPHIA and REHOVOT, Israel, June 28, 2011 /PRNewswire/ – Rosetta Genomics (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announces it has entered into a collaboration with the University of California,  Davis (“UC Davis” or the “University”) to develop and validate a microRNA profile for muscle-invasive bladder cancer (MI-BC) that is predictive of patient response to neoadjuvant chemotherapy.  The collaboration allows for UC Davis researchers to continue using Rosetta’s platforms and microRNAs to further discover new biomarkers and validate their results.

Researchers have initiated collaborations by studying 55 MI-BC patients treated at UC Davis Cancer Center with neoadjuvant chemotherapy. The primary goal of this study is to develop and validate a microRNA profile of MI-BC that is predictive of patient response to neoadjuvant chemotherapy.  A secondary goal of the study is to understand the mechanism by which differentially expressed microRNAs mediate chemosensitivity.

Approximately 30 percent of bladder cancer patients present with or will develop MI-BC, which has a five-year survival rate of approximately 50 percent.  Evidence-based medicine has clearly demonstrated the survival benefit of [click to continue…]

{ 0 comments }